The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for September 2024 (PDF).
This issue contains the precautionary recommendations for men taking valproate containing medicines that was published earlier this month. Due to the potential for an increased risk of neurodevelopmental disorders it is recommended that men on valproate are made aware of these risks and that effective contraception is used during treatment and for three months after treatment stops.
Lastly, this issue contains a summary of letters to healthcare professionals in August. These generally related to supply issues and recalls.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.